Withum Sounding Board

The episode contains several genuinely useful frameworks - IP/Revenue/Margin inflection points mapped to investor classes, the clinical-stage-asset overhang thesis, and dilution math - but is diluted by generic advice on pivoting, grit, and board transparency that adds little for a sophisticated operator.

“I look at it as IP inflection first, revenue inflection second and margin inflection third. And there's a different class of investors for each.”

“if you're going to have a third dilution for each round of financing and you have three rounds of financing, that's what, two thirds times two thirds times two thirds, which is two, four, eight ninths”

The clinical-stage-asset overhang explanation - why pre-clinical companies can't raise because clinical-stage zombie companies crowd out capital - is a genuinely underappreciated structural point; the rest (pivot often, be transparent, outsource early) is standard startup doctrine.

“for 50% more cost, 50% more price, you can cut the risk in half. So you know, the numbers could be all over the place. But that's just an illustration of why we are in the state we're in with this biotech valley of death”

“Those companies were very successful. During COVID when there was, there was a high degree of adoption for sightless clinical trials. But those companies have for the most part failed.”

Greg Ammon is a genuine multi-stage practitioner - six companies built, four sold, EIR at Mass General Brigham, active angel investor reviewing ~16 deals/year, and a Harvard lecturer - giving him real credibility across pre-clinical through late-stage pharma, though he's not a household-name operator at billion-dollar scale.

“of the six companies I built, three of them were VC backed and three of them weren't. Four of them were had exits and two of them failed”

“when I was eir at ah, Mass General Brigham...I worked on a few hundred academic research projects”

The Science 37 SPAC collapse ($3.5B to $50-60M) and the failure-rate statistics (88% pre-Phase 2, 46% Phase 2 to approval) are concrete and memorable; however, the guest hedges several figures with 'something like' and 'could be all over the place,' and the outsourcing headcount thresholds (100, 200, 500-1000 employees) feel rule-of-thumb rather than data-backed.

“Science 37 as example. Their SPAC was three and a half billion dollars and they sold for 50 or 60 million dollars”

“it's something like 88% of all the drug candidates fail between when they're identified to the phase 2 clinical trial”

The host asks broad setup questions and rarely follows up on genuinely interesting threads - for example, she doesn't probe the Science 37 cautionary tale, the 88%/46% failure-rate source, or the tension between Greg's own bootstrap choice and his advice to raise - and responses like 'Yeah, so far' and 'Very good, very good' signal a largely unchallenging PR-style format.

“Yeah, so far.”

“Very good, very good.”